ProShare Advisors
ACRS icon

ProShare Advisors’s Aclaris Therapeutics ACRS Stock Holding History

ProShare Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106K Buy
20,095
+1,399
+7% +$6.24K ﹤0.01% 1763
2026
Q1 		$70.1K Sell
18,696
-2,857
-13% -$9.64K ﹤0.01% 1753
2025
Q4 		$64.9K Buy
21,553
+6,734
+45% +$17K ﹤0.01% 1928
2025
Q3 		$28.2K Sell
14,819
-3,794
-20% -$6.61K ﹤0.01% 1974
2025
Q2 		$26.4K Buy
+18,613
New +$25.2K ﹤0.01% 2051
2024
Q3 		– Sell
-13,701
Closed -$15.1K – 2066
2024
Q2 		$15.1K Sell
13,701
-3,749
-21% -$4.41K ﹤0.01% 1821
2024
Q1 		$21.6K Buy
17,450
+1,430
+9% +$1.71K ﹤0.01% 1970
2023
Q4 		$16.8K Buy
16,020
+2,361
+17% +$7.2K ﹤0.01% 1925
2023
Q3 		$93.6K Buy
13,659
+53
+0.4% +$453 ﹤0.01% 1645
2023
Q2 		$141K Buy
13,606
+1,378
+11% +$12.5K ﹤0.01% 1625
2023
Q1 		$98.9K Sell
12,228
-1,600
-12% -$20.3K ﹤0.01% 1592
2022
Q4 		$218K Buy
13,828
+1,098
+9% +$17.7K ﹤0.01% 1442
2022
Q3 		$201K Buy
12,730
+823
+7% +$13K ﹤0.01% 1408
2022
Q2 		$167K Sell
11,907
-3,998
-25% -$56K ﹤0.01% 1515
2022
Q1 		$274K Sell
15,905
-3,855
-20% -$52.6K ﹤0.01% 1688
2021
Q4 		$287K Buy
+19,760
New +$299K ﹤0.01% 1816
2021
Q3 		– Sell
-11,264
Closed -$198K – 2004
2021
Q2 		$198K Buy
+11,264
New +$256K ﹤0.01% 2150
2019
Q4 		– Sell
-14,710
Closed -$16K – 1790
2019
Q3 		$16K Sell
14,710
-1,088
-7% -$1.54K ﹤0.01% 1645
2019
Q2 		$35K Sell
15,798
-1,957
-11% -$10.7K ﹤0.01% 1588
2019
Q1 		$106K Buy
17,755
+148
+0.8% +$981 ﹤0.01% 1567
2018
Q4 		$130K Buy
17,607
+1,704
+11% +$17.6K ﹤0.01% 1439
2018
Q3 		$231K Sell
15,903
-607
-4% -$10.4K ﹤0.01% 1503
2018
Q2 		$330K Sell
16,510
-718
-4% -$13.3K ﹤0.01% 1325
2018
Q1 		$302K Sell
17,228
-2,837
-14% -$60.1K ﹤0.01% 1314
2017
Q4 		$495K Buy
+20,065
New +$489K ﹤0.01% 1137

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

ProShare Advisors's ACRS Position: Q2 2026 in Review

ProShare Advisors increased its Aclaris Therapeutics (ACRS) stake by 7.5% in Q2 2026, buying an estimated $6.24K and bringing the position to 20,095 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #1763.

ProShare Advisors first reported a position in ACRS in Q4 2017 and has held it in 25 quarters since. The position peaked at $495K in Q4 2017. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • ProShare Advisors held 20,095 shares of Aclaris Therapeutics worth $106K as of Q2 2026.
  • ProShare Advisors bought 1,399 Aclaris Therapeutics shares in Q2 2026, an estimated $6.24K.
  • Aclaris Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1763 holding.
  • ProShare Advisors first reported a position in Aclaris Therapeutics in Q4 2017 and has held it in 25 quarters since.
  • ProShare Advisors's Aclaris Therapeutics position peaked at $495K in Q4 2017.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.